Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-04, Vol.386 (14), p.1377-1380
Hauptverfasser:	Regev-Yochay, Gili, Gonen, Tal, Gilboa, Mayan, Mandelboim, Michal, Indenbaum, Victoria, Amit, Sharon, Meltzer, Lilac, Asraf, Keren, Cohen, Carmit, Fluss, Ronen, Biber, Asaf, Nemet, Ital, Kliker, Limor, Joseph, Gili, Doolman, Ram, Mendelson, Ella, Freedman, Laurence S, Harats, Dror, Kreiss, Yitshak, Lustig, Yaniv
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Confidence intervals Coronavirus Coronaviruses Correspondence COVID-19 COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - therapeutic use Health care Humans Immunization, Secondary - methods Infections Infectious Disease Medical personnel mRNA mRNA vaccines mRNA Vaccines - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine Efficacy Vaccines Vaccines, Synthetic Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2202542